Program
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010
Its studies are led by HC Biopharma.
Furthest: phase 2, since Aug 26, 20252 company-led studies, 2 open or runningNext primary completion: Dec 30, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HC Biopharma | 22 open or running | phase 2since Aug 26, 2025 | Mar 6, 2024 | Dec 30, 2026phase 2 · NCT07169552 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 6, 2024First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06307925 · 122 planned · China
- Aug 26, 2025Phase 2 study in NSCLCNCT07169552 · 50 planned · China
Ahead
- Dec 30, 2026Primary completion: phase 2 study in NSCLCNCT07169552
TargetBeta
“A trispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), and the human vascular endothelial growth factor (VEGF), ”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07169552NSCLC · China | 2 | Recruiting | Dec 30, 2026 | 50 |
| NCT06307925Carcinoma, Non-Small-Cell Lung · China | 1 | Recruiting | Dec 31, 2025 | 122 |
How it is read
Names in the registry
- “HC010”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.